Primbs G B, Casey R, Wamser K, Snyder W J, Crean D H
Jules Stein Eye Institute, University of California at Los Angeles, USA.
Ophthalmic Surg Lasers. 1998 Oct;29(10):832-8.
Photodynamic therapy with tin ethyl etiopurpurin (SnET2) was evaluated as a treatment modality for rat corneal neovascularization.
Escalating light doses at 664 nm were applied focally to corneal neovascularization in rats 10 minutes following an intravenous injection of SnET2 using a low-power diode laser. Controls consisted of light-only and drug-only treatments. Clinical, angiographic, and histopathologic evaluations were performed on the animals up to 28 days after drug and/or light treatment.
A drug and light dose-response was seen in producing neovessel closure. In animals treated with SnET2 and the highest light dose (25 J/cm2), all eyes showed occlusion at every follow-up evaluation up to 28 days. Control eyes demonstrated progressive disease at all time points.
Photodynamic therapy appears to be safe and effective for eliciting prolonged (> 28 days) occlusion of corneal neovascularization in the rat model with minimal side effects and good clinical outcomes.
评估用乙磺卟啉锡（SnET2）进行光动力疗法治疗大鼠角膜新生血管的疗效。
静脉注射SnET2 10分钟后，使用低功率二极管激光器，以递增的光剂量在664nm波长下对大鼠角膜新生血管进行局部照射。对照组包括单纯光照和单纯药物治疗。在药物和/或光照治疗后长达28天的时间里，对动物进行临床、血管造影和组织病理学评估。
在促使新生血管闭合方面观察到药物和光剂量反应。在用SnET2和最高光剂量（25J/cm²）治疗的动物中，直至28天的每次随访评估时，所有眼睛均显示血管闭塞。对照眼在所有时间点均表现为病情进展。
在大鼠模型中，光动力疗法对于引发角膜新生血管的长期（>28天）闭塞似乎是安全有效的，副作用极小且临床效果良好。
